Share on StockTwits

Shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) were the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 11,451,419 shares, an increase of 28.6% from the April 30th total of 8,904,611 shares, Stock Ratings Network reports. Approximately 23.1% of the shares of the company are sold short. Based on an average daily trading volume, of 1,634,258 shares, the short-interest ratio is presently 7.0 days.

A number of analysts have recently weighed in on AUXL shares. Analysts at MKM Partners upgraded shares of Auxilium Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Wednesday, May 28th. They now have a $26.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at TheStreet downgraded shares of Auxilium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Auxilium Pharmaceuticals in a research note on Thursday, May 22nd. They now have a $33.00 price target on the stock, down previously from $34.00. Four equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $26.79.

Shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) opened at 22.38 on Monday. Auxilium Pharmaceuticals has a 52 week low of $14.74 and a 52 week high of $32.89. The stock has a 50-day moving average of $23.0 and a 200-day moving average of $24.03. The company’s market cap is $1.124 billion.

Auxilium Pharmaceuticals (NASDAQ:AUXL) last announced its earnings results on Monday, May 5th. The company reported ($0.39) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.17) by $0.22. The company had revenue of $8.50 million for the quarter, compared to the consensus estimate of $89.20 million. During the same quarter last year, the company posted ($0.05) earnings per share. Auxilium Pharmaceuticals’s revenue was up 33.7% compared to the same quarter last year. On average, analysts predict that Auxilium Pharmaceuticals will post $-0.18 earnings per share for the current fiscal year.

Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.